US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

296.31

+0.55000.19%

Post-market: 295.02-1.2900-0.44%19:59 EDT

Volume:260.53K

Turnover:75.10M

Market Cap:570.24M

PE:- -

High:300.34

Open:290.97

Low:281.50

Close:295.76

52wk High:341.93

52wk Low:71.88

Shares:1.92M

Float Shares:1.92M

Volume Ratio:0.69

T/O Rate:13.54%

Dividend:1.01

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Argenx's Vyvgart Hytrulo Likely to Get FDA Approval for Myositis, RBC Says

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Insight Molecular Diagnostics (IMDX) and Innovent Biologics (OtherIVBXF)

Amylyx Phase 3 data support FDA approval, says Citi

Analysts Offer Insights on Healthcare Companies: Vivani Medical (VANI) and InspireMD (NSPR)

GE HealthCare Appoints William Grogan as New CFO

Oncolytics Biotech gains FDA alignment on REO 033 trial

GRAIL (GRAL) Is Down 6.5% After FDA Sets Galleri PMA Panel Review – Has The Bull Case Changed?

Simply Wall St.

Sector Update: Healthcare Stocks Flat to Higher Premarket Tuesday

MT Newswires Live

Oncolytics aligns with FDA on path for REO 033 expansion study

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

BlossomHill Says BH-30643 Gets FDA Fast Track Designation in Non-Small Cell Lung Cancer

MT Newswires Live

BlossomHill Therapeutics receives fast track designation for BH-30643 from FDA

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

Analysts Offer Insights on Healthcare Companies: Invivyd (IVVD), Traws Pharma (TRAW) and DocGo (DCGO)

Celltrion's Acquired French Healthcare Firm Becomes Fully Operational

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC) and Heron Therapeutics (HRTX)

Ping An Healthcare and Technology Publishes Unaudited 2026 Interim Results

BAIC Vice President Shi Zhishan's Annual Pay Reaches 754,100 Yuan, Trailing Peer Hu Hanjun for Second Straight Year

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/LABU/news?page=20"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":296.31,"timestamp":1788206400000,"preClose":295.76,"halted":0,"volume":260525,"hourTrading":{"tag":"盘后","latestPrice":295.02,"preClose":296.31,"latestTime":"19:59 EDT","volume":2518,"amount":745089.4272,"timestamp":1788220773434,"change":-1.29,"changeRate":-0.004354,"amplitude":0.010268},"delay":0,"changeRate":0.0018596159047877042,"floatShares":1924486,"shares":1924486,"eps":0,"marketStatus":"Not Yet Opened","change":0.55,"latestTime":"08-31 16:00:00 EDT","open":290.97,"high":300.34,"low":281.5,"amount":75101085.83125001,"amplitude":0.0637,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":295.76,"sharesOutstanding":3074486,"nav":295.545,"aum":568772231.45,"dividendRate":0.0034,"bidAskSpread":0.002847,"preHourTrading":{"tag":"盘前","latestPrice":288.18,"preClose":295.76,"latestTime":"09:29 EDT","volume":1523,"amount":449603.04808999994,"timestamp":1788182999999,"change":-7.58,"changeRate":-0.025629,"amplitude":0.050003},"postHourTrading":{"tag":"盘后","latestPrice":295.02,"preClose":296.31,"latestTime":"19:59 EDT","volume":2518,"amount":745089.4272,"timestamp":1788220773434,"change":-1.29,"changeRate":-0.004354,"amplitude":0.010268},"volumeRatio":0.686734,"impliedVol":0.9253,"impliedVolPercentile":0.5777},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1924486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.686734,"shares":1924486,"dividePrice":1.0075,"high":300.34,"amplitude":0.0637,"preClose":295.76,"low":281.5,"week52Low":71.88,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":296.31,"eps":0,"divideRate":0.0034,"volume":260525,"delay":0,"ttmEps":0,"open":290.97,"prevYearClose":159.39,"prevWeekClose":295.76,"prevMonthClose":227.4,"prevQuarterClose":292.1,"fiveDayClose":308.33,"twentyDayClose":228.04,"sixtyDayClose":179.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:20,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660495503","title":"Argenx's Vyvgart Hytrulo Likely to Get FDA Approval for Myositis, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2660495503","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660495503?lang=en_us&edition=fundamental","pubTime":"2026-08-18 23:06","pubTimestamp":1787065592,"startTime":"0","endTime":"0","summary":"Argenx's (ARGX) Vyvgart Hytrulo is likely to get approval from the US Food and Drug Administration for adults with immune-mediated necrotizing myopathy and dermatomyositis, RBC Capital Markets analyst","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1983260115.SGD","LU0823416689.USD","BK4505","LABU","IE00BJJMRZ35.SGD","LU0109394709.USD","FMED","BK4585","BK4588","IE00BJT1NW94.SGD","LU0320765992.SGD","IE0002141913.USD","IE0034235188.USD","LU0889565916.HKD","LU2324357040.USD","IE0009355771.USD","BK4139","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IBB","TBXU","ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660493221","title":"Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Insight Molecular Diagnostics (IMDX) and Innovent Biologics (OtherIVBXF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660493221","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660493221?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:40","pubTimestamp":1787064009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amylyx Pharmaceuticals Inc (AMLX), Insight Molecular...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amylyx-pharmaceuticals-inc-amlx-insight-molecular-diagnostics-imdx-and-innovent-biologics-otherivbxf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amylyx-pharmaceuticals-inc-amlx-insight-molecular-diagnostics-imdx-and-innovent-biologics-otherivbxf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMLX","BK4588","BK4137","LU0128526141.USD","HCSG","XLV","IMDX","LABU","LU0029874061.USD","BK4581","BK4007","XBI","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660595493","title":"Amylyx Phase 3 data support FDA approval, says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2660595493","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660595493?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:05","pubTimestamp":1787061936,"startTime":"0","endTime":"0","summary":"Citi says Amylyx’s (AMLX) avexitide showed a “highly differentiated” profile in the Phase 3 LUCIDITY study, a 78 participant, placebo-controlled tr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-phase-3-data-support-fda-approval-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-phase-3-data-support-fda-approval-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNX","BK4007","FRTY","PINK","BK4588","BBP","IBB","TBXU","IDNA","AMLX","LFSC","TECB","SYNB","RSPH","IEIH","IYH","GNMX","BMED","NVIB","XLVX","LABU","MEDI","GDOC","PSCH","BK4585","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660498488","title":"Analysts Offer Insights on Healthcare Companies: Vivani Medical (VANI) and InspireMD (NSPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660498488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660498488?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:00","pubTimestamp":1787061614,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vivani Medical (VANI) and InspireMD (NSPR) with bull...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vivani-medical-vani-and-inspiremd-nspr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vivani-medical-vani-and-inspiremd-nspr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4082","BK4588","XLV","VANI","LABU","BK4198","LU0128526141.USD","XBI","BK4581","BK4137","NSPR","HCSG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660498800","title":"GE HealthCare Appoints William Grogan as New CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2660498800","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660498800?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:33","pubTimestamp":1787060032,"startTime":"0","endTime":"0","summary":"GE Healthcare Technologies Inc ( ($GEHC) ) has shared an update. On August 13, 2026, GE HealthCare Technologies Inc. appointed William K. Grogan as...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ge-healthcare-appoints-william-grogan-as-new-cfo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ge-healthcare-appoints-william-grogan-as-new-cfo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1551013425.SGD","LU0689472784.USD","NATO","LU1066051225.USD","XBI","LU1066053197.SGD","LU2168564065.EUR","MISL","UXI","BK4581","LU2168564149.EUR","PPA","LU1064131342.USD","LU1119994496.HKD","ITA","TRUI","XLV","BK4187","LU1093756168.USD","LU2756315318.SGD","BK4501","LU2543165471.USD","LU0267386448.USD","BK4585","BK4566","LU0943347566.SGD","LU0640476718.USD","LU2087625088.SGD","LU1261432733.SGD","LU0353189763.USD","LU1366333091.USD","LU0149725797.USD","LU1093756325.SGD","BK4588","LU2168564495.EUR","XAR","LU0868494617.USD","GE","DFEN","LU0077335932.USD","LU0353189680.USD","LU0820561909.HKD","LU1066051498.USD","LU2264538146.SGD","LU2168564222.USD","BK4543","EXI","LU1066051811.HKD","LU0157215616.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660498362","title":"Oncolytics Biotech gains FDA alignment on REO 033 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660498362","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660498362?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:33","pubTimestamp":1787060008,"startTime":"0","endTime":"0","summary":"An update from Oncolytics Biotech ( ($ONCY) ) is now available. On August 18, 2026, Oncolytics Biotech Inc. reported it had received written feedba...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oncolytics-biotech-gains-fda-alignment-on-reo-033-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oncolytics-biotech-gains-fda-alignment-on-reo-033-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","BK4585","XBI","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660084498","title":"GRAIL (GRAL) Is Down 6.5% After FDA Sets Galleri PMA Panel Review – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660084498","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660084498?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:28","pubTimestamp":1787059732,"startTime":"0","endTime":"0","summary":"GRAIL announced that the FDA’s Molecular and Clinical Genetics Panel will meet on September 23, 2026, to review the Premarket Approval application for its Galleri multi-cancer early detection blood test, which targets cancer-specific methylation patterns and is intended to complement existing screening methods.\nThis review marks a major regulatory inflection point for what GRAIL describes as the only multi-cancer early detection test backed by large interventional and randomized, controlled...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-is-down-65-after-fda-sets-galleri-pma-panel-revie","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-is-down-65-after-fda-sets-galleri-pma-panel-revie","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4129","PMA","BK4139","LABU","GRAL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660609344","title":"Sector Update: Healthcare Stocks Flat to Higher Premarket Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2660609344","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660609344?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:17","pubTimestamp":1787059061,"startTime":"0","endTime":"0","summary":"Health care stocks were flat to higher premarket Tuesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.7%.Amylyx Pharm","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4581","XLV","BK4139","BK4588","XBI","AMLX","BLSM","HCSG","BK4585","IBB","LU0128526141.USD","LU0029874061.USD","IMTX","BK4137","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660604674","title":"Oncolytics aligns with FDA on path for REO 033 expansion study","url":"https://stock-news.laohu8.com/highlight/detail?id=2660604674","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660604674?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:16","pubTimestamp":1787058974,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) announced that it has received written feedback from the FDA regarding the design of a potential pivotal Part B expansion of REO ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-aligns-with-fda-on-path-for-reo-033-expansion-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-aligns-with-fda-on-path-for-reo-033-expansion-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY","BK4588","BK4139","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660460749","title":"DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List","url":"https://stock-news.laohu8.com/highlight/detail?id=2660460749","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660460749?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:02","pubTimestamp":1787058120,"startTime":"0","endTime":"0","summary":"National recognition comes as Daré Bioscience advances a multi-product women’s health strategy across commercialization, clinical development and first-in-category innovationSAN DIEGO, Aug.  18, 2026 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/18/3346918/30757/en/dar%C3%A9-bioscience-ceo-sabrina-martucci-johnson-named-to-forbes-2026-50-over-50-innovation-list.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FXG","BK4007","LU0345780950.USD","LU0256331488.USD","LU0630314457.HKD","LU2380233275.USD","LU2211817866.USD","BK4189","DAR","LU1803068623.USD","LU0345781412.USD","LU1721429402.USD","LU0106261612.USD","LU1721429741.USD","LU0012050646.USD","LU2308191902.HKD","BK4584","DARE","BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660607464","title":"Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660607464","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660607464?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:00","pubTimestamp":1787058000,"startTime":"0","endTime":"0","summary":"FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/18/3346884/0/en/oncolytics-biotech-aligns-with-fda-on-registrational-path-for-second-line-ras-mutant-mss-colorectal-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XBI","BK4113","LABU","MSS","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660467384","title":"Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2660467384","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660467384?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:30","pubTimestamp":1787056200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Aug.  18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administratio","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/18/3346838/0/en/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-101095-in-combination-with-pembrolizumab-for-the-treatment-of-ici-refractory-solid-tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","LENZ","BK4585","BK4588","LABU","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660446439","title":"BlossomHill Says BH-30643 Gets FDA Fast Track Designation in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660446439","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660446439?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:30","pubTimestamp":1787052613,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics (BLSM) said Tuesday the US Food and Drug Administration has granted fast track designation for BH-30643 in advanced or metastatic epidermal growth factor receptor C797S-positi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLSM","BK4209","LABU","BK4585","BH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461071","title":"BlossomHill Therapeutics receives fast track designation for BH-30643 from FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461071?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:10","pubTimestamp":1787051413,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics (BLSM) announced that the FDA has granted fast track designation to BH-30643 for the treatment of adult patients with adva...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-receives-fast-track-designation-for-bh-30643-from-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-receives-fast-track-designation-for-bh-30643-from-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4585","LENZ","BK4588","BK4209","BK4539","BLSM","BH","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660464507","title":"BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2660464507","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660464507?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:00","pubTimestamp":1787050800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Aug.  18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/18/3346704/0/en/blossomhill-therapeutics-announces-fda-fast-track-designation-for-bh-30643-a-macrocyclic-omni-egfr-inhibitor-for-the-treatment-of-advanced-egfr-c797s-positive-nsclc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4209","BK4585","IE00B7SZL793.SGD","LENZ","BK4157","IE0031619046.USD","LU1815336091.USD","LABU","AEIS","LU2931357623.SGD","BK4007","LU2089985449.USD","BK4539","IE00B19Z4B17.USD","LU0274383776.USD","BK4588","LU0757428866.USD","BK4139","IE00B66KJ199.SGD","BH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660696174","title":"Analysts Offer Insights on Healthcare Companies: Invivyd (IVVD), Traws Pharma (TRAW) and DocGo (DCGO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660696174","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660696174?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:20","pubTimestamp":1787048425,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Invivyd (IVVD), Traws Pharma (TRAW) and DocGo (DCG...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-invivyd-ivvd-traws-pharma-traw-and-docgo-dcgo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-invivyd-ivvd-traws-pharma-traw-and-docgo-dcgo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4196","BK4139","BK4581","XLV","DCGO","HCSG","LU0128526141.USD","LU0029874061.USD","IVVD","BK4539","TRAW","BK4585","BK4007","BK4137","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660465984","title":"Celltrion's Acquired French Healthcare Firm Becomes Fully Operational","url":"https://stock-news.laohu8.com/highlight/detail?id=2660465984","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660465984?lang=en_us&edition=fundamental","pubTime":"2026-08-18 17:28","pubTimestamp":1787045317,"startTime":"0","endTime":"0","summary":"Celltrion's  French healthcare unit Gifrer has begun full-scale operations following the completion of post-acquisition integration and restructuring.The company expects Gifrer's network of more than 9,000 pharmacies and over 800 hospitals to help expand its reach, according to a Tuesday press release.Celltrion plans to use the pharmacy network to sell its subcutaneous biosimilars and non-competing third-party healthcare products, while also launching its derma cosmetics brand Zipiderm in France.The company aims to use France as a test market before gradually expanding the pharmacy sales model across Europe, subject to local regulations and distribution structures.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLV","HCSG","LABU","BK4588","BK4137","BK4585","XBI","LU0128526141.USD","BK4581","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660465689","title":"Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC) and Heron Therapeutics (HRTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660465689","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660465689?lang=en_us&edition=fundamental","pubTime":"2026-08-18 17:20","pubTimestamp":1787044808,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Irhythm Technologies (IRTC) and Heron Therapeutics (HRTX). Irhyth...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-irhythm-technologies-irtc-and-heron-therapeutics-hrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-irhythm-technologies-irtc-and-heron-therapeutics-hrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","LABU","BK4139","BK4588","LU0029874061.USD","BK4137","IRTC","XLV","BK4581","BK4082","HRTX","XBI","BK4585","BK4563","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660465510","title":"Ping An Healthcare and Technology Publishes Unaudited 2026 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2660465510","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660465510?lang=en_us&edition=fundamental","pubTime":"2026-08-18 17:17","pubTimestamp":1787044671,"startTime":"0","endTime":"0","summary":"Ping An Healthcare and Technology Company ( ($HK:1833) ) has provided an update. Ping An Healthcare and Technology Company Limited, a Hong Kong-lis...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ping-an-healthcare-and-technology-publishes-unaudited-2026-interim-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ping-an-healthcare-and-technology-publishes-unaudited-2026-interim-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","LU0128526141.USD","XBI","BK4137","BK4581","LABU","LU0029874061.USD","PAImain","BK4585","BK4588","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150672410","title":"BAIC Vice President Shi Zhishan's Annual Pay Reaches 754,100 Yuan, Trailing Peer Hu Hanjun for Second Straight Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1150672410","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150672410?lang=en_us&edition=fundamental","pubTime":"2026-08-18 16:30","pubTimestamp":1787041836,"startTime":"0","endTime":"0","summary":"Recent disclosures from BAIC Group have revealed the 2024 executive compensation packages, with Vice Presidents Hu Hanjun and Shi Zhishan having each received only 10 months of salary in 2023. The...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XLV","LABU","BK4581","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":20,"totalSize":402,"code":"91000000","status":"200"}]}}